pharma · Clostridium Difficile Infection · Ulcerative Colitis · MCRB
Seres Therapeutics
Seres Therapeutics patent portfolio — 36 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2010
- Employees
- 129
- Programs
- 8
- Drugs
- 7
- Patents
- 36
Seres Therapeutics patents
36 pharmaceutical patents indexed for Seres Therapeutics. 0 expire within 24 months.
Seres Therapeutics has 36 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12409197
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 12214002
Compositions and methods for treating antibiotic resistance
granted -
US 12083151
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11918612
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11730775
Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof
granted -
US 11701394
Compositions and methods for treating cholestatic disease
granted -
US 11666612
Network-based microbial compositions and methods
granted -
US 11464812
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11458173
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11458174
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11389490
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11266699
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11185562
Compositions and methods for inhibition of pathogenic bacterial growth
granted -
US 10973861
Compositions and methods
granted -
US 10967011
Compositions and methods
granted -
US 10881696
Network-based microbial compositions and methods
granted -
US 10864235
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 10258655
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 10076546
Network-based microbial compositions and methods
granted -
US 10064900
Methods of populating a gastrointestinal tract
granted -
US 10064901
Compositions and methods
granted -
US 9956282
Bacterial compositions and methods of use thereof for treatment of immune system disorders
granted -
US 9855303
Compositions and methods
granted -
US 9757483
Labeled iodinated tropane formulation
granted -
US 9585921
Compositions and methods
granted -
US 9533014
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 9446080
Compositions and methods
granted -
US 9180147
Compositions and methods
granted -
US 9028841
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 9011834
Compositions and methods
granted -
US 8986653
Labeled iodinated tropane formulation
granted -
US 8906668
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 8574545
Labeled iodinated tropane formulation
granted -
US 8133861
Systemic purine administration: modulating axonal outgrowth of central nervous system neurons
granted -
US 8084018
Methods for imaging dopamine transporter level
granted -
US 7452866
Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1
granted
Frequently asked questions
How many patents does Seres Therapeutics have?
36 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Seres Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.